Shannon Campbell was appointed Director of Zentalis Pharmaceuticals, Inc., effective May 22, 2026. As of November 6, 2026, Zentalis Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 27, 2026, naming 1 appointment (Form 8-K, May 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Zentalis Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Zentalis Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-27. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Zentalis Pharmaceuticals, Inc. files it.
Also on the record for Zentalis Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.1% of the class | 5%+ stakes | Source |
| August 19, 2026 | Stake report, Schedule 13G/A, by Walters William T | 18.8% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Barclays PLC | 3.17% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.2% of the class | 5%+ stakes | Source |
| March 3, 2026 | Stake report, Schedule 13G, by Squadron Master Fund LP | 5.1% of the class | 5%+ stakes | Source |
| January 5, 2026 | Stake report, Schedule 13G/A, by Walters William T | 19.7% of the class | 5%+ stakes | Source |
| January 2, 2026 | Stake report, Schedule 13D/A, by Matrix Capital Management Company, LP | — | 5%+ stakes | Source |
| December 30, 2025 | Stake report, Schedule 13G, by Andrew J. Schwab | 6.4% of the class | 5%+ stakes | Source |
| December 15, 2025 | Stake report, Schedule 13D/A, by Matrix Capital Management Company, LP | 9.98% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by Barclays PLC | 5.32% of the class | 5%+ stakes | Source |
| October 14, 2025 | Stake report, Schedule 13G/A, by Millennium Management LLC | 1.3% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 2.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zentalis Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Zentalis Pharmaceuticals, Inc. and the records around it.
Zentalis Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Matrix Capital Management Company, LP also filed stake reports on 2 other companies: Aura Biosciences, Inc. (May 2026), Maze Therapeutics, Inc. (Nov 2025)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
Watch Zentalis Pharmaceuticals, Inc.
Get an email when Zentalis Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zentalis Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Zentalis Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zentalis Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-27 | In | Director | 2026-05-22 | 8-K, 2026-05-27 |
Who leads Zentalis Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Shannon Campbell, appointed, effective 2026-05-22 (filed 2026-05-27).
New leaders reset buying decisions — get the Full Report on Zentalis Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Zentalis Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Director at Zentalis Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Shannon Campbell, Director, effective 2026-05-22
Effective May 22, 2026, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
- Ms. Campbell's initial term is scheduled to expire at the Company's 2027 Annual Meeting of Stockholders, subject to the election and qualification of her successor and her earlier death, resignation or removal.
- Ms. Campbell has also been appointed to serve on the Compensation Committee of the Board (the "Compensation Committee").
- In accordance with the Director Compensation Program, as a new non-employee director, Ms. Campbell was granted restricted stock units ("RSUs") covering 114,200 shares of the Company's common stock on May 26, 2026, which number of shares was determined by multiplying (i) the number of common shares outstanding as of the day prior to the date of grant, by (ii) 0.16% (such percentage determined by the board).
- The initial RSU grant vests over three years with one-third of the underlying shares vesting on each of the first, second and third anniversaries of the date of grant.
- Also in accordance with the Director Compensation Program, after Ms. Campbell has served on the Board for at least six months, Ms. Campbell is entitled to receive an annual equity grant on the date of the Company's next annual meeting of stockholders of RSUs covering that number of shares of the Company's common stock as is determined by multiplying (i) the number of common shares outstanding as of the day prior to the date of grant, by (ii) 0.08%.
Tools for this story
Each opens in a new tab, filled in for Zentalis Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.